Pyxis Oncology Company

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Funding Status: IPO
Industry: Gene therapy
Headquarters: Boston, Massachusetts, United States
Total Funding: 174000000
Last Funding Date: 2021
Last Funding Type: Series B
Investor Type: Early Stage Venture
Employee Number: 11-50
Investors Number: 21
Founded Date: 2019-01-01